EUCTR2004-002811-98-IT进行中（未招募）不适用
Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE0 个研究点目标入组 100 人开始时间: 2007年2月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to explore the effects of cetuximab alone or in combination with irinotecan in patients with an abnormal gene (KRAS) in their colon cancer cells.metastatic colorectal cancerEUCTR2012-003638-18-ESAustralasian Gastro-Intestinal Trials Group, Sydney University100
进行中（未招募）
1 期
A study to explore the effects of cetuximab alone or in combination with irinotecan in patients with an abnormal gene (KRAS) in their colon cancer cells.metastatic colorectal cancerEUCTR2012-003638-18-BEAustralasian Gastro-Intestinal Trials Group, Sydney University100
进行中（未招募）
不适用
A study to explore the effects of cetuximab alone or in combination with irinotecan in patients with an abnormal gene (KRAS) in their colon cancer cells.EUCTR2012-003638-18-GBAustralasian Gastro-Intestinal Trials Group, Sydney University100
进行中（未招募）
1 期
ICE CREAM: The Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients with G13D MutatioEUCTR2012-003638-18-ITAGITG (Australasian Gastro - Intestinal Trial Group)100
进行中（未招募）
1 期
Randomised phase II study with cetuximab (Erbitux®) in combination with 5-FU and cisplatin or carboplatin versus CETuximab (Erbitux®) in combination with paclitaxel and carboplatin for treatment of patients with relapsed or METastatic squamous cell carcinoma of the head and neck - CETMETPatients with metastatic or recurrent squamous cell carcinoma of the head and neck, not suitable for local treatmentMedDRA version: 19.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022924-57-DKRadiumhemmet, Karolinska University Hospital, Stockholm, Sweden120